Here, we propose a panel of candidate predictive biomarkers (such as PHGDH, UBA1, RBKS, GNA13, IGFBP7, CA2, and VSIG4) and a panel of candidate diagnostic biomarkers (such as TRAF2, AGT, IL18R1, ISLR2, GC, RBKS, and WFIKKN1) for AMS. This evidence concerns the gene UBA1 and ablepharon macrostomia syndrome.